MeiraGTx/MGTX

$5.56

-4.01%
-
1D1W1MYTD1YMAX

About MeiraGTx

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.

Ticker

MGTX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Alexandria Forbes

Employees

419

Headquarters

New york, United States

MeiraGTx Metrics

BasicAdvanced
$353.62M
Market cap
-
P/E ratio
-$1.58
EPS
1.28
Beta
-
Dividend rate
$353.62M
1.27987
$8.35
$3.49
145.77K
2.38
52.193
52.193
-91.62%
-26.06%
-65.67%
-33.89%
25.228
2.559
2.58
-11.95%
44.98%
-3.43%

What the Analysts think about MeiraGTx

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 5 analysts.
288.49% upside
High $36.00
Low $11.00
$5.56
Current price
$21.60
Average price target

MeiraGTx Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
1,010% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$2M
-60.78%
Net income
$20.2M
-145.7%
Profit margin
1,010%
-216.54%

MeiraGTx Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 270.59%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.62
-$0.53
-$0.74
-$0.42
-
Expected
-$0.66
-$0.57
-$0.55
-$0.11
-$0.51
Surprise
-5.58%
-6.47%
35.37%
270.59%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for MeiraGTx stock?

MeiraGTx (MGTX) has a market cap of $353.62M as of April 14, 2024.

What is the P/E ratio for MeiraGTx stock?

The price to earnings (P/E) ratio for MeiraGTx (MGTX) stock is 0 as of April 14, 2024.

Does MeiraGTx stock pay dividends?

No, MeiraGTx (MGTX) stock does not pay dividends to its shareholders as of April 14, 2024.

When is the next MeiraGTx dividend payment date?

MeiraGTx (MGTX) stock does not pay dividends to its shareholders.

What is the beta indicator for MeiraGTx?

MeiraGTx (MGTX) has a beta rating of 1.28. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the MeiraGTx stock price target?

The target price for MeiraGTx (MGTX) stock is $21.6, which is 288.49% above the current price of $5.56. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell MeiraGTx stock

Buy or sell MeiraGTx stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing